FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286299162> ?p ?o ?g. }

• W4286299162 endingPage "525" @default.
• W4286299162 startingPage "525" @default.
• W4286299162 abstract "525 Background: Homologous recombination deficiency (HRD) status can be used to identify patients who are eligible for treatment with DNA damaging agents. Using a 3-biomarker Genomic Instability Score (GIS) threshold of ≥42, studies have previously examined the association between HRD status and outcomes in patients with triple negative breast cancer (TNBC). However, evidence suggests that a GIS threshold of ≥33 may be more appropriate. Here, we conducted an exploratory analysis evaluating the ability of ≥33 and ≥42 GIS thresholds to predict response to platinum-based treatment in patients with TNBC. Methods: Patients across 5 cohorts (TBCRC030 1 , TBCRC008 2 , NCT01372579 3 , PrECOG 0105 4 , combined cisplatin cohort 4 ) were included in this analysis if they had a primary TNBC diagnosis, received neoadjuvant platinum-based treatment, had a valid GIS, and had known pathologic complete response (pCR) status. GIS was determined by a combination of loss of heterozygosity, telomeric-allelic imbalance, and large-scale state transitions. 4,5 BRCA mutation status was defined by loss of function resulting from a pathogenic variant in BRCA1 or BRCA2. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated by comparing binary threshold status and binary pCR status. Results: A total of 204 tumors (158 BRCAwt; 33 BRCAm; 13 unknown) were included; pCR to platinum-based treatment occurred in 55 cases (39 BRCAwt; 14 BRCAm; 2 unknown). Sensitivity, specificity, PPV, and NPV were comparable between the ≥33 and ≥42 GIS thresholds, with the ≥33 threshold producing higher sensitivity values. This was true when thresholds were applied to all samples and to BRCAwt samples only (Table). Among patients who achieved pCR in response to platinum-based treatment, 5.5% of patients in the full cohort and 7.7% of those in the BRCAwt cohort had a GIS between 33-41. Conclusions: To ensure that the majority of patients likely to benefit from treatment are identified, a GIS of ≥33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective trial will be needed to confirm these findings. Additional studies will be important to determine whether this threshold may be appropriate to determine eligibility for other DNA-damaging agents such as PARP inhibitors. 1. Ann Oncol. 2020;31(11):1518-25 2. J Nucl Med. 2015;56(1):31-7. 3. Breast Cancer Res Treat. 2015;151(3):629-38. 4. Clin Cancer Res. 2016;22(15):3764-73. 5. Breast Cancer Res Treat. 2014;16(6):1-9. [Table: see text]" @default.
• W4286299162 created "2022-07-21" @default.
• W4286299162 creator A5004542056 @default.
• W4286299162 creator A5008665323 @default.
• W4286299162 creator A5015821699 @default.
• W4286299162 creator A5016027202 @default.
• W4286299162 creator A5020438734 @default.
• W4286299162 creator A5022192136 @default.
• W4286299162 creator A5033544737 @default.
• W4286299162 creator A5041593789 @default.
• W4286299162 creator A5047918797 @default.
• W4286299162 creator A5051532432 @default.
• W4286299162 creator A5052487618 @default.
• W4286299162 creator A5053390874 @default.
• W4286299162 creator A5056530735 @default.
• W4286299162 creator A5066125634 @default.
• W4286299162 creator A5073728088 @default.
• W4286299162 creator A5075816825 @default.
• W4286299162 creator A5075889627 @default.
• W4286299162 creator A5078696948 @default.
• W4286299162 creator A5085028425 @default.
• W4286299162 creator A5085329460 @default.
• W4286299162 date "2022-06-01" @default.
• W4286299162 modified "2023-10-02" @default.
• W4286299162 title "Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer." @default.
• W4286299162 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.525" @default.
• W4286299162 hasPublicationYear "2022" @default.
• W4286299162 type Work @default.
• W4286299162 citedByCount "0" @default.
• W4286299162 crossrefType "journal-article" @default.
• W4286299162 hasAuthorship W4286299162A5004542056 @default.
• W4286299162 hasAuthorship W4286299162A5008665323 @default.
• W4286299162 hasAuthorship W4286299162A5015821699 @default.
• W4286299162 hasAuthorship W4286299162A5016027202 @default.
• W4286299162 hasAuthorship W4286299162A5020438734 @default.
• W4286299162 hasAuthorship W4286299162A5022192136 @default.
• W4286299162 hasAuthorship W4286299162A5033544737 @default.
• W4286299162 hasAuthorship W4286299162A5041593789 @default.
• W4286299162 hasAuthorship W4286299162A5047918797 @default.
• W4286299162 hasAuthorship W4286299162A5051532432 @default.
• W4286299162 hasAuthorship W4286299162A5052487618 @default.
• W4286299162 hasAuthorship W4286299162A5053390874 @default.
• W4286299162 hasAuthorship W4286299162A5056530735 @default.
• W4286299162 hasAuthorship W4286299162A5066125634 @default.
• W4286299162 hasAuthorship W4286299162A5073728088 @default.
• W4286299162 hasAuthorship W4286299162A5075816825 @default.
• W4286299162 hasAuthorship W4286299162A5075889627 @default.
• W4286299162 hasAuthorship W4286299162A5078696948 @default.
• W4286299162 hasAuthorship W4286299162A5085028425 @default.
• W4286299162 hasAuthorship W4286299162A5085329460 @default.
• W4286299162 hasConcept C102744134 @default.
• W4286299162 hasConcept C104317684 @default.
• W4286299162 hasConcept C121608353 @default.
• W4286299162 hasConcept C126322002 @default.
• W4286299162 hasConcept C143589142 @default.
• W4286299162 hasConcept C143998085 @default.
• W4286299162 hasConcept C180754005 @default.
• W4286299162 hasConcept C2776694085 @default.
• W4286299162 hasConcept C2778239845 @default.
• W4286299162 hasConcept C2780110267 @default.
• W4286299162 hasConcept C2780194787 @default.
• W4286299162 hasConcept C2781197716 @default.
• W4286299162 hasConcept C530470458 @default.
• W4286299162 hasConcept C54355233 @default.
• W4286299162 hasConcept C71924100 @default.
• W4286299162 hasConcept C72563966 @default.
• W4286299162 hasConcept C86803240 @default.
• W4286299162 hasConceptScore W4286299162C102744134 @default.
• W4286299162 hasConceptScore W4286299162C104317684 @default.
• W4286299162 hasConceptScore W4286299162C121608353 @default.
• W4286299162 hasConceptScore W4286299162C126322002 @default.
• W4286299162 hasConceptScore W4286299162C143589142 @default.
• W4286299162 hasConceptScore W4286299162C143998085 @default.
• W4286299162 hasConceptScore W4286299162C180754005 @default.
• W4286299162 hasConceptScore W4286299162C2776694085 @default.
• W4286299162 hasConceptScore W4286299162C2778239845 @default.
• W4286299162 hasConceptScore W4286299162C2780110267 @default.
• W4286299162 hasConceptScore W4286299162C2780194787 @default.
• W4286299162 hasConceptScore W4286299162C2781197716 @default.
• W4286299162 hasConceptScore W4286299162C530470458 @default.
• W4286299162 hasConceptScore W4286299162C54355233 @default.
• W4286299162 hasConceptScore W4286299162C71924100 @default.
• W4286299162 hasConceptScore W4286299162C72563966 @default.
• W4286299162 hasConceptScore W4286299162C86803240 @default.
• W4286299162 hasFunder F4320316995 @default.
• W4286299162 hasFunder F4320332161 @default.
• W4286299162 hasIssue "16_suppl" @default.
• W4286299162 hasLocation W42862991621 @default.
• W4286299162 hasOpenAccess W4286299162 @default.
• W4286299162 hasPrimaryLocation W42862991621 @default.
• W4286299162 hasRelatedWork W2109772731 @default.
• W4286299162 hasRelatedWork W2245189862 @default.
• W4286299162 hasRelatedWork W2340990597 @default.
• W4286299162 hasRelatedWork W2534174115 @default.
• W4286299162 hasRelatedWork W2621993462 @default.
• W4286299162 hasRelatedWork W2969907252 @default.
• W4286299162 hasRelatedWork W3133785871 @default.
• W4286299162 hasRelatedWork W363598932 @default.

• next